News

The companies believe urokinase-based drug combination has an opportunity to significantly improve upon the current standard of cancer therapy. Microbix made a large investment this year in its

The expanded analysis focuses on the 61 patients with an AP23573 clinical-benefit response – the primary end-point of the 212-patient trial – and its relation to progression-free survival.

Tercica licensed from Ipsen the rights to develop and market Somatuline Autogel in the US and Canada in a transaction that closed on October 13, 2006. “Ipsen’s submission

The collaboration is intended to capitalize on Xoma’s comprehensive antibody discovery, development and production technologies. Payments to Xoma could exceed $100 million before royalties over the life of

The company said there would be a delay in the clinical program for XL999 of between two weeks and three months until further data have been collected and

TG100801, applied daily in eye drop form, is designed to suppress disease-related edema, angiogenesis and inflammation, which are all pathological hallmarks of macular degeneration. Currently approved therapies for

In addition, ongoing studies of GelVac formulations incorporating influenza antigens exhibited the potential for long-term stability during storage at room temperature. The data showed the antigens were protected

Merck said that inclusion of the vaccine in the health care program would make it more accessible. Gardasil was approved on June 8 by the FDA for use

Under the terms of the agreement, Inspire has acquired exclusive rights to develop and commercialize oral formulations of bilastine in the US and Canada, as well as the